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Abstract
Phenotype is a collection of an organism's observable features that can be characterized both on indi-
vidual level and on single cell level. Phenotypes are largely determined by their molecular processes
which also explain their inheritance and plasticity. Some of the molecular background of phenotypes
can be characterized by inherited genetic variations and alterations in gene expression.
The high-throughput measurement technologies enable the measurement of molecular determi-
nants in cells. However, measurement technologies produce remarkable large data sets and the re-
search questions have become increasingly complex. Thus computational methods are needed to
discover molecular mechanisms behind the phenotypes. In many cases, analysis of molecular deter-
minants that contribute to the phenotype proceeds by ﬁrst identifying putative candidates by using
a priori information and high-throughput measurements. Then further analysis can focus on most
promising molecules. In many cases, the aim is to identify relevant markers or targets from a set of
candidate molecules.
Often biomedical studies result in a long list of candidate genes, and to interpret these candidates,
information on their context in cell molecular functions is needed. This context information can give
insight to synergistic eﬀects of molecular machinery in cells when functions of individual molecules
do not explain the observed phenotype. In addition, the context information can be used to generate
candidates. One of the methods in this thesis provides a computational data integration method that
provides a link in between candidate genes from molecular pathways and genetic variants. It uses
publicly available biological knowledge bases to systematically create functional context of candidate
genes. This approach is especially important when studying cancer, that is dependent of complex
molecular signaling.
Genotypes associated with inherited disease predispositions have been studied successfully in the
past, however, traditional methods are not applicable in wide variety of analysis conditions. Thus, this
thesis introduces a method that uses haplotype sharing to identify genetic loci inherited by multiple
distantly related individuals. It is ﬂexible and can be used in various settings, also with very limited
number of samples.
Increasing the number of biological replicates in gene expression analysis increases the reliability
of the results. In many cases, however, the number of samples is limited. Therefore, pooling gene
expression data from multiple published studies can increase the understanding of the molecular
background behind cell types. This is shown in this thesis by an analysis that identiﬁes gene expression
diﬀerences in two cell types using publicly available gene expression samples from previous studies.
Finally, when candidate molecules are available to characterize phenotypes, they can be compiled
into biomarkers. In many cases, a combination of multiple molecules serves as a better biomarker
than a single molecule. This thesis also includes a machine learning approach that is used to discover
a classiﬁer that predicts the phenotype.
v
Tiivistelmä
Fenotyyppi on joukko organismin piirteitä, jotka ovat havaittavissa joko yksilön tasolla tai yksittäisten
solujen tasolla. Molekulaariset prosessit määräävät pitkälti fenotyyppien ilmentymistä, joten taustalla
vaikuttavat molekulaariset prosessit myös selittävät fenotyyppien perinnöllisyyttä sekä mukautumista.
Fenotyyppien molekulaarista taustaa voidaan kartoittaa tunnistamalla geneettistä variaatiota sekä
muutoksia geenien aktiivisuudessa.
Määrääviä molekulaarisia tekijöitä voidaan havaita soluissa käyttämällä high-throughput -mittaus-
teknologioita. Nämä mittausteknologiat tuottavat erittäin suuria data-aineistoja, ja samalla tutkimus-
kysymykset ovat tulleet entistä monimutkaisemmiksi. Nämä seikat ovat johtaneet siihen, että lasken-
nallisia menetelmiä tarvitaan fenotyyppien molekulaarisen mekanismien tunnistamisessa. Usein tutki-
mus etenee ensin tunnistamalla lupaavia kandidaatteja käyttämällä aiempaa tietoa sekä high-through-
put -mittauksia. Jatkoanalyysit voivat keskittyä lupaavimpiin molekyyleihin. Tällöin tavoitteena
saattaa olla käyttökelpoisimpien biomarkkereiden tunnistaminen tai kohdegeenien valitseminen kan-
didaattien joukosta.
Usein biolääketieteen tutkimus tuottaa ison joukon kandidaattigeenejä, jolloin tulosten tulkinta
vaatii tietoa kandidaattigeenien suhteesta solun muuhun molekulaariseen toimintaan. Kun tämä
molekulaarinen toiminta kontekstina otetaan huomioon, on mahdollista ymmärtää geenien yhteis-
vaikutuksia solun toimintaan silloin kun yksittäiset geenit eivät selitä havaittua fenotyyppiä. Solun
molekulaarista kontekstia voi käyttää myös kandidaattigeenien kartoittamiseen. Yksi tässä väitöskir-
jassa esitelty menetelmä tarjoaa laskennallisen menetelmän, jolla voidaan yhdistää kandidaatit tunne-
tuilta pathwaylta geneettisiin variantteihin. Tämä menetelmä käyttää julkisia tietokantoja, joista se
systemaattisesti kerää molekulaarisen kontekstin kandidaattigeeneille. Tällainen lähestymistapa on
erityisen hyödyllinen syöpätutkimuksessa, sillä syöpä on tyypillisesti riippuvainen monimutkaisista
molekyylien signalointiverkoista.
Perittyjen genotyyppien ja sairauksien välisiä yhteyksiä on tutkittu pitkään menestyksekkäästi,
mutta perinteisesti käytetyt menetelmät soveltuvat vain tiettyihin tapauksiin. Tässä väitöskirjassa
esitellään menetelmä, joka käyttää haplotyyppien jakamista tunnistaakseen genomiset alueet, jotka
ovat periytyneet useille kaukaisesti sukua oleville henkilöille. Tätä menetelmää voi käyttää useissa eri-
laisissa tutkimuskysymyksissä, ja se tuottaa luotettavia tuloksia myös hyvin vähäisellä näytemäärällä.
Geeniekspressioanalyysin tulosten luotettavuus kasvaa samalla kun biologisten kopioiden määrä
aineistossa kasvaa. Huolimatta tästä, näytemäärät ovat usein rajallisia. Tämän vuoksi geeniekspres-
siomittausten yhdistäminen useista jo julkaistuista tutkimuksista voi lisätä ymmärrystä solutyypin
määräävistä biologisista prosesseista. Tässä väitöskirjassa esitellään analyysi, jolla tunnistetaan gee-
niekspressioeroja käyttäen geeniekspressioainestoa, joka on yhdistetty julkaistuista tutkimuksista.
Viimein, kun fenotyyppiä selittävät kandidaattimolekyylit on tunnistettu, niistä voidaan luoda
biomarkkereita. Monesti useamman molekyylin mittaus on parempi biomarkkeri kuin yksikään
molekyyli yksinään. Tässä väitöskirjassa esitellään myös koneoppimisanalyysi, jolla luodaan gee-
niekspressiomittauksista fenotyyppiä ennustava luokittelija.
vi
1 Introduction
1 Introduction
Computational methods are essential in biomedical research when studying molecular mechanisms
that determine, for instance, what creates organisms' appearance, makes them susceptible to a dis-
ease, or induces them to behave as they do. The computational methods can be used to quantify
diﬀerences in molecule concentrations in diﬀerent types of cells. As measurement technologies evolve
and our understanding of biology increases, computational methods need to be developed to meet
new demands.
The topic of this work originates from traditional paradigm in medicine, or natural sciences in
general, where understanding of a natural phenomenon can be solved by dissecting the question into
the study of individual components [1]. This paradigm in science, reductionism, is the principle
when studying molecular mechanisms that determine a phenotype, which is an organism's observable
feature, such as eye color. Reductionistic paradigm assumes one-to-one mapping between a molecule,
such as gene product, and the phenotype [2]. This approach is evident in medicine, where the
research aims to identify the dysfunctional organ or molecule, and return the normal, healthy, state
by repairing the problem [1]. Similarly, the estimators for disease risks are typically based on single
molecule biomarkers and each disease is typically treated individually without a holistic view of a
patient's physical state [1].
One limitation of reductionism is that it misses the interactions and multiplicative eﬀects of
the components in a complex biological system [1]. This has pushed biomedical research to study
complete biological functions at the systems level. Systems biology assumes that the whole system has
synergistic characteristics that cannot be seen from individual components [1, 2]. In this paradigm,
computational approaches are in a central role as systems biology includes computational models
and biological measurements [1, 3]. The carefully designed measurements verify the accuracy of the
models, although molecular biology is still lacking the rich datasets that, for example, chemistry has
[3].
Although reductionism has limitations due to overly simpliﬁed assumptions, it has also shown
its power in biomedicine [1]. However, increasingly complex datasets and computational approaches
have been produced to address the questions of biomedicine at systems-level [4, 5]. Thus, no single
approach can explain the complex nature of phenotypes, which calls for approaches that target the
research question on diﬀerent levels.
Biomedical research requires understanding of the system level functions of the molecules, in-
heritance of phenotypes, the phenotypic plasticity in tissue types, and, in the end, it also requires
translating these into clinical tools such as biomarkers. In Publication I we present how the molec-
ular determinants can be estimated using a priori knowledge from molecular systems. Publication
II and Publication III present two complementary approaches to identify candidate genes behind
the phenotype. In Publication II we use genetics in a setting where the phenotype is inherited from
a common ancestor. In Publication III we analyze gene expression and combine biologically and
technically versatile data, and identify candidate genes where changes in expression change the phe-
notype of the cell types. To use these candidate genes clinically, they can be compiled into biomarkers
or their synergistic eﬀects can be studied computationally. In Publication IV we identify a gene
expression signature that predicts the phenotype.
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The ﬁrst aim of this chapter is to deﬁne the biological goals and review the molecular mechanisms
known to aﬀect phenotypes. The second aim is to address the measurement technologies that produce
information from the molecular level. Finally, the relevant computational analysis approaches are
reviewed.
2.1 Genetic regulation and inheritance of phenotypic variation
The concepts of phenotypes and their inheritance can be viewed both from individual-level (organism)
and from sub-individual level (cell types or cell colonies) [6]. The inheritance of phenotypes on both
of these levels are explained by genetic inheritance (DNA) [6] and epigenetic inheritance (regulation
of DNA and chromatin) [7]. The genetic and epigenetic inheritance together contribute to a cell's
molecular functions that can be observed as cell type speciﬁc gene expression [8].
2.1.1 Phenotypes
On an organismal level, a phenotype is the organism's whole collection of observable physical com-
ponents; the component may be morphology, behavior, or molecular function [9, 10]. In many cases,
like in this thesis, phenotype actually refers to a partial phenotype [9], that consists only of those
components that are interesting or relevant in given context, i.e., disease phenotype in comparison to
disease-free phenotype. Thus, understanding the biology behind a partial phenotype is the guiding
principle in this thesis.
Phenotype can be something as obvious as eye color. Organisms can also be classiﬁed according
to the phenotype that is common to them [9], such as walking in an upright position or the ability
to produce language. Species-speciﬁc phenotypes are examples of such groupings [9]. On cell type
level, the phenotype can be seen as species-speciﬁc phenotype for cell types, that is the collection of
physical components that is common to all cells in that cell type.
Phenotype is determined by the inherited material (which is reviewed in the next section), and
by the environment [10]. When including the environmental factors into phenotype determinants,
phenotypes tend to be plastic both on organismal level [11] and on single cell or cell population
level [12]. In this thesis molecular regulation of a cell is considered as an inherited determinant of a
phenotype and only the external signals to be environmental factors.
2.1.2 Inheritance of phenotypes
The phenotype passed on from one generation of biological entities, such as organisms or single
cells, to another follows the like-begets-like phenomenon [6], where the oﬀspring usually resemble the
parent. Diﬀerences on individual and sub-individual level may be inherited in genetic (in DNA) or
epigenetic (regulation of DNA and chromatin) manner. According to, the nowadays disputed [13, 14],
'central dogma' of biology [15], all inherited information is stored in the DNA molecule, from which
the RNA molecule is transcribed and this messenger RNA (mRNA) is later translated into proteins
that perform the functions of the cells. This process is illustrated in Figure 2.1. According to this
dogma, genetic inheritance is explained by transmission of DNA from parents to oﬀspring [6], and
features of the DNA molecule translate to phenotype through messenger RNA (mRNA), protein, and
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Figure 2.1: The schematic representation of the process that conveys the information from DNA to
the phenotype, which is also referred as 'central dogma' of biology. DNA double helix is opened, and
the messenger RNA (mRNA) is transcribed from the DNA template. The protein is synthesized from
the mRNA molecule in a cell's cytoplasm.
protein functions or through functions of non-coding RNA [16, 17]. Meanwhile, epigenetic inheritance
functions without changes in the DNA sequence through epigenetic modiﬁcations and regulation of
cell signaling [18, 7], but also through the maintenance and transmission of DNA [18].
Essentially, the inherited genetic or epigenetic features are manifested in the phenotype through
molecular signaling: the type of produced molecules, the rate of molecule production or success of
molecular interactions. At a single cell level, the inherited part of a phenotype is determined by the
information content of DNA [19] and the regulation of intrinsic molecular signaling [20].
The central part of inheritance, both on individual and sub-individual level, is DNA transmission
from parent to oﬀspring [6]. The biological basis of this DNA transmission is well characterized in
sexual reproduction, in meiosis, and in eukaryote cell division, in mitosis. Procaryotes and viruses
also transmit DNA (or RNA) to their oﬀspring, but this thesis is concentrated only on mechanisms
in eukaryote cells.
In sexual reproduction, both parents transmit haploid chromosomes to the oﬀspring that receives
diploid chromosomes combined of the parents' genomes. The parents' haploid chromosomes are
produced in meiotic cell division, which has two cell divisions but only one DNA replication [19].
Interesting parts of meiosis are the dissociation of parental chromosomes and the recombination, where
homologous parental chromosomes exchange parts of the DNA chain. This, in principle, produces a
random selection from paternal and maternal genomic sequences transmitted to the oﬀspring. Mitosis,
instead, produces two diploid daughter cells that have nearly identical copies of the chromosomes.
Epigenetic inheritance takes place on the single cell (sub-individual) level [7], it follows DNA
transmission in cell division, although the inherited information is not in the DNA sequence [7].
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Figure 2.2: An example of a pedigree diagram. The inheritance of phenotypes can be visualized
using a pedigree diagram as shown by this ﬁgure. The squares are males and the circles females, and
individuals are connected to their spouses with direct horizontal lines. The children are below their
parents and connected to them with vertical lines. A slash through a symbol means that this individual
is deceased. [Figure downloaded 21.1.2013 from http://en.wikipedia.org/wiki/File:Pedigree-chart-
example.png]
Epigenetic information is based on methylation of DNA and several diﬀerent histone modiﬁcations
[7, 18] that have an eﬀect on DNA transcription, which propagates to changes in phenotype [7, 18].
Although it is important to recognize the eﬀect of epigenetics to molecular functions and phenotypes,
it is out of the scope of this thesis.
The inheritance of phenotypes is typically visualized with a pedigree chart as in Figure 2.2. Various
studies have revealed a causative genetic component in the inheritance of many human phenotypes
such as eye color [21], neuroﬁbramatosis [11] or colorectal cancer [22]. However, transmission of DNA
alone does not explain the inheritance of phenotypes [6, 11]. Although non-genetic part of inheritance
is often explained by environmental factors[6], also epigenetic inheritance may be an important factor
that can contribute to inheritance of phenotypes.
2.1.3 Cell types
All cells in an organism inherit their DNA from a common progenitor. Although some genetic
changes accumulate during cell generations, cell type speciﬁc phenotypes are typically determined by
regulation of gene expression [20, 23]. An example of morphological diﬀerences between cell types is
shown in Figure 2.3.
During the development of an organism, the phenotype is altered by the environmental signals that
trigger transcription factors that either promote or suppress the target genes' expression by binding
to DNA [24, 20]. For instance, the gene POU domain, class 5, transcription factor 1 (Oct-3/4 ) has
been identiﬁed as a switch whose expression regulates diﬀerentiation from stem cells [25]. During an
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Figure 2.3: A) Undiﬀerentiated human embryonic stem cells and B) neurons developed from the
human embryonic stem cells. All the cells carry nearly identical DNA and still show dramatically
diﬀerent phenotypes. The cell types diﬀerentiate during development and commit to this phenotype.
This image is published in PLoS Biology [26] under Commons Attribution 2.5 license (link to the ﬁle
19.11.2012 http://en.wikipedia.org/wiki/File:Human_embryonic_stem_cells.png)
organism's development, cells diﬀerentiate and cell populations maintain their diﬀerentiation [24, 23].
In biomedicine, the cell type speciﬁc molecular signatures provide attractive biomarkers and may
serve as selective drug targets [8]. In addition to environmental signals for transcription factors, the
sub-individual inheritance of phenotype from cell generation to another is partly due to epigenetic
regulation of cell fate [24]. Thus, the gene expression regulation is an interplay between epigenetic
modiﬁcations and transcription factor responses to signals.
The cell type speciﬁc phenotype is a result of complex molecular signaling, which can be described
in terms of molecular signaling pathways. As gene expression produces the interacting molecules in
the molecular signaling pathways, the signaling in these pathways may change when gene expression
changes, as for example in the apoptosis pathway [27]. One example of transcription factors is the
widely studied tumor protein 53 (tp53) that responses to various stress signals [28, 29]. Once a cell
confronts stress, such as double-stranded DNA breakage, tp53 activation in the cell increases and
its ability to upregulate target genes' expression increases [28, 29]. The result may be an activation
of an apoptosis pathway, whose schematic diagram from WikiPathways [30] is given in Figure 2.4.
Although the molecular signaling pathways usually involve gene products instead of DNA, for sake
of simplicity, we can assume one-to-one mapping of genes to their protein products and call proteins
in these pathways with corresponding gene names and focus on studies of gene expression.
Several studies have identiﬁed tissue type speciﬁc gene expression signatures [31, 32, 8] that show
commitment of cell types to to express their speciﬁc phenotypes. These experiments have accumulated
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Figure 2.4: The molecule signaling diagram from the apoptosis pathway. This diagram represents a
model for gene activation and repression. The squares are proteins of which we can assume a one-
to-one mapping to genes, and the lines are interactions between these proteins. Proteins in the same
boxes form complexes. Blocked lines illustrate repression and arrows activation. In this diagram, the
red lines indicate the activation signals of apoptosis and blue lines repression of apoptosis. Image was
downloaded from WikiPathways at 27.9.2012.
data to phenotype databases that deﬁne gene expression patterns in tissue or cell types [10, 33, 34].
2.1.4 Cancer cells
Cancer cells represent a subtype of cell types that have acquired a phenotype that allows uncon-
trollable growth of the cell population and invasion into surrounding tissues, which may create a life
threatening disease by disturbing the normal functions of the body [35]. Although cancers are a group
of heterogeneous malignant growths from diﬀerent tissue origins, similar molecular functionalities can
be seen in all cancers [36].
The established hallmarks of cancer cells are proliferation, escape from growth restriction, inva-
sion to other tissues, unlimited number of cell cycles, ability to introduce angiogenesis and escape
from apoptosis [36, 37]. In contrast to normal cell populations, cancer cells' phenotype is due to
accumulated somatic mutations [37, 38], especially through genomic instability [36, 37], and addi-
tional epigenetic modiﬁcations during cell generations [37, 39]. Figure 2.5 visualizes the steps that a
cancer cell population has undergone during the disease development. Cancer cells grow in a colony
where the cell population is under massive evolutionary selection [37, 38], which results bias to some
beneﬁcial genetic and epigenetic changes.
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Figure 2.5: Cancer cells acquire somatic mutations which lead to an altered phenotype, which can
create a disease by uncontrolled growth of cancer cells and their invasion to other tissues. This
ﬁgure is published by the National Cancer Institute under public domain. (Link to ﬁle 19.11.2012,
http://en.wikipedia.org/wiki/File: Cancer_requires_multiple_mutations_from_NIHen.png)
Cancer originates from normal cells that, along cell generations, undergo several changes before
they develop into a life-threatening disease [37]. In some of the cases, the initial chromosomal changes
are inherited in the germline, which manifests as an increased risk of cancer [22, 40]. Some of the
inherited genetic risk is associated with common genetic variants, which can be observed at the
population level [40]. However, one genetic or epigenetic change alone is not suﬃcient to create cancer
[37], of this colorectal cancer is a good example. Colorectal cancers have, in many cases, concurrent
tp53 inactivation with other mutations in genes such as liver kinase B1 (LKB1 ) or adenomatous
polyposis coli (APC ) [22]. Cancer cells are typically characterized by altered molecular signaling
pathways. For example, classical cancer pathways are those regulated by tp53, thus tp53 is deregulated
either directly or indirectly in many diﬀerent types of cancers [41], such as breast cancer [4].
2.1.5 Biomarkers
A biomarker is a measurable feature that can be used to detect biological processes and success of
treatments [42]. Additionally, the deﬁnition of molecular biomarker has been extended to all possible
biomarkers and biomarker combinations that can be detected using their molecular features [43]. The
classiﬁcation of the biomarkers varies depending on the context where the biomarker is intended to
be used: is it targeted, for instance, to identify cell types or assess organism-level phenotypes, such
as diseases [44]. The biomarkers can be based on the molecular background of the phenotype or
some non-molecular feature, such as blood pressure [42]. Also, the biomarker may be the cause of
the phenotype or it can be only a surrogate marker [45].
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Biomarkers are widely used in disease screening for early-onset diseases [44, 46], diagnostics [46],
prognosis [47, 48, 49, 46] and selecting treatments [49, 46]. Breast cancer, for example, has an
established classiﬁcation system that is based on biomarkers regarding tumor size, metastasis and
lymph nodes [50], and additional molecular biomarkers identiﬁed from gene expression [51, 48]. The
biomarkers can be used as surrogates to predict the disease outcome [42, 44], which is especially useful
in drug trials [42]. In addition, molecular markers can be used to identify and monitor tissue or cell
types [52, 53]. One example of a widely studied molecular biomarker is Oct-3/4, which has been used
to identify undiﬀerentiated stem cells [54, 53].
2.2 Measurement technologies
DNA is the building block of inheritance, and gene expression is the well characterized molecular basis
of cell type speciﬁc phenotype in multicellular organisms. Therefore, the measurement technologies
reviewed are those to discover the identity of DNA (genetic variation), and those to quantify the gene
expression intensity (amount of mRNA).
2.2.1 Genetics
Genetic measurement technologies are based on the genetic variation proﬁle of an individual. In each
locus, each individual has two possible alleles of base pairs that constitute a genotype. Genotyping
technologies aim to characterize the genotypes along the genome.
SNP microarrays Single nucleotide polymorphism (SNP) is a variant that is polymorphic in a
given population, i.e., it has a minor allele frequency, which is the allele frequency of rarer allele in
a population, higher than some predeﬁned threshold, such as 5% [55]. Biallelic (two possible alleles
in a population) SNPs are used as a genotyping surrogates in SNP microarrays [56, 55, 57]. One
individual can be distinguished from others by measuring a suﬃcient number of SNPs. In meiosis,
parental chromosomes can be recombined to form a new chromosome for oﬀspring that has DNA
stretches from both parental chromosomes. In a population this leads to a phenomenon called linkage
disequilibrium (LD), where DNA regions tend to be observed in blocks, which is usually measured by
correlation between loci [55, 57]. The concept of using SNPs in genotyping is based on an assumption
that a SNP tags the DNA region that is in LD with the SNP. Thus, by measuring these SNPs we
actually indirectly measure the identity of the surrounding DNA region [55].
A SNP microarray contains single-stranded complementary DNA (cDNA) probes for biallelic SNPs
that have been selected to the array [56, 57]. The principle of SNP microarray technology is illustrated
in Figure 2.6. The probes are organized into probe sets having one probe set for allele A and one
for allele B [56]. The single-stranded and fragmented sample DNA is hybridized on the probes in the
array and the hybridized probes then contain label, usually biotin, to capture the signal [56, 57]. Next
the array is scanned and the image is read for the genotypes [56]. The signal is measured from probe
sets for alleles A and B, and the loci is determined either to be homozygous AA or BB genotype or
heterozygous AB genotype, and the SNP locus is mapped to the probe location in the array [56, 57].
Sequencing A direct way to detect genotypes from any species is sequencing, and the most recent
sequencing technologies are rapidly growing in popularity over the SNP microarray genotyping. The
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Figure 2.6: Schematic illustration of the SNP array technology. Original ﬁgure is in Karinen, S. 2008.
benchmark technique is Sanger sequencing, which is generally feasible in sequencing limited chromo-
somal regions [58, 59]. The Sanger sequencing uses a DNA template where DNA is generated by
polymerase chain reaction, which is terminated by a dideoxyribonucleotide [59]. The sequence length
is determined by each of the four sequence terminating nucleotides, which enables deduction of the
order of nucleotide sequence [59]. The Sanger method is today used merely for validation purposes
[58].
Currently, the newest sequencing technologies enable sequencing of the whole genome or selected
regions, such as protein coding regions (exome sequencing) [58]. The sequencing technologies are
developing rapidly [58], but the standard scheme in various platforms is to generate base pair calls
for a read, which is a string of DNA from one hundred to more than thousand nucleotides long [60].
These reads overlap, which creates a read coverage along the genome [61]. The actual sequence is
inferred from these overlapping reads.
Measurements produced by sequencing were not used in the publications in this thesis, however,
recognizing the importance sequencing technologies is essential for modern biomedical research. Also,
the methods presented in this thesis to analyze genetic variation can be applied to data derived from
sequencing technologies, as well.
2.2.2 Gene expression
Gene expression measurement quantiﬁes the level of mRNA transcribed from genes [62]. Gene ex-
pression can be measured either from selected genes of interest or genome-wide from all the genes.
The selected technology depends on the target: expression of a small set of genes can be measured
with reverse-transcription quantitative polymerase chain reaction (RT-qPCR) [62], the whole-genome
expression proﬁle can be captured with gene expression microarray technologies [63], and the most
comprehensive whole-genome expression quantiﬁcation can be achieved with RNA sequencing (RNA-
seq) [64].
RT-qPCR Reverse-transcription quantitative polymerase chain reaction (RT-qPCR) can be used to
quantify gene expression of selected genes from up to a thousand samples, and it is especially useful
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in biomarker deployment [62]. RT-qPCR is highly sensitive, economical [65], and it can produce
measurements from a very limited amount of RNA.
In RT-qPCR, RNA is converted into cDNA using reverse-transcription, which is then ampliﬁed
by using PCR for a pre-determined number of cycles and the relative concentration is then quantiﬁed
[62]. Real-time qPCR allows simultaneous ampliﬁcation and detection of the RNA [62]. The detection
is based on ﬂuorescence dyes that are attached to reporter sequences, that in turn bind or hybridize
on the target molecule [62]. The amount of cDNA doubles at each PCR cycle, therefore the expression
values require speciﬁc transformation steps. In the analysis, RT-qPCR data can be used as absolute
values or relative expression values [62]. For the relative gene expression quantiﬁcation, a housekeeping
gene is used as an internal control to subtract the expression value from pre-deﬁned PCR cycle
threshold (Ct) [65] from target genes' value in Ct to get the gene-speciﬁc value 4Ct [62, 66]. An
outside calibrator sample can also be used to get the normalized value 44Ct between assays that is
usually reported as 2−44Ct [66, 62].
Gene expression microarrays Gene expression microarrays follow the same principle as SNP
genotyping microarrays. They have cDNA probes attached on an array where target DNA is hy-
bridized and the ﬂuorescence signal is scanned by special ﬂuorescence microscopy from the microarray,
and the target is then identiﬁed using probe position coordinates in the microarray [67, 68]. In the
gene expression microarrays, however, the target DNA is produced using reverse-transcription from
mRNA [67, 69]. The probes selected for the microarray measure the expression of the target gene.
Several commercial providers oﬀer gene expression microarrays having diﬀerent technical solutions,
such as one-channel or two-channel signal [70].
The one-channel Aﬀymetrix platform has perfect match (PM) probe sets that consist of multiple
perfectly matching 25 nucleotides long oligonucleotides and corresponding mismatch (MM) oligos
with one nucleotide diﬀerence in the middle of the probe [68]. Labeled cDNA from a single sample
is hybridized on these probes. These probes can be mapped to the most up-to-date annotations to
obtain mRNA measurements from correct chromosomal loci, and the gene-speciﬁc expression can be
combined from the probes that are mapped to the same gene [68]. The two-channel microarrays
provided by Agilent can hybridize two samples having diﬀerent labels [70]. One subtype of gene
expression microarrays is an exon array, whose high density probes aim to capture expression of
individual exons. This measurement technology enables to quantify expression of alternatively spliced
transcripts [71].
The raw values from the gene expression microarray are rarely used, but a normalization step
follows the reading of the data to account for background and inter-array diﬀerences [63]. The
normalization method is selected according to the used measurement technology, and it aﬀects the
data quality [72], however, there are no deﬁnite guidelines on how to select the optimal normalization
method [73].
RNA-seq RNA-seq is currently the most advanced gene expression quantiﬁcation method as it
allows measuring the level of all RNA in the cell as well as determining speciﬁc transcripts [62,
64]. However, RNA-seq is a relatively new technology, especially when compared to qPCR, whose
development was initiated from discovery of PCR in 1983 [62]. In comparison to DNA sequencing,
the RNA-seq technology has additional complexity because it aims to quantify the gene expression
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instead of just giving distinct judgment of the presence of a variant [74]. The RNA-seq also starts
from reverse-transcription that transforms the target RNA into cDNA, which is then sequenced to
obtain data of overlapping reads [74]. The RNA level is then quantiﬁed from these overlapping reads.
Data produced by RNA-seq were not used in publications of this thesis. However, use of the
RNA-seq measurement technology is increasing, and computational method in Publication IV can
also be applied to RNA-seq data.
2.3 Computational methods to analyze molecular basis of phenotypes
The human genome consists of approximately 3 billion bases and 20,000 protein coding genes, where
the regulation of molecular mechanisms is complex [75]. Thus, it is evident that computational
methods are required to understand the DNA-originated molecular mechanisms behind phenotypes.
The computational methods reviewed in this section either aim to identify molecular candidates
behind the phenotype or compile these candidates into a clinically relevant predictive model. This
separation of the computational methods follows an approach in biomedicine where the understanding
of complete processes is initiated by identifying a set of candidate molecules that is then analyzed to
prioritize the ﬁndings [76] or integrated into more complex functional models [77].
The mining of molecular determinants can be based on genotype or gene expression data. The
mining is typically dependent on the existing biological knowledge, and this knowledge is used as a
reference to interpret results, to rank the ﬁndings, or to create hypotheses for an analysis [76]. One
example of existing biological knowledge is the human genome that is used as reference basis for
research in biomedicine [75].
A clinically relevant model can be a diagnostic or prognostic predictor. Methods to discover these
predictors typically use the candidate molecules produced by the mining and create an application
that selects biomarkers for a model that predicts the phenotype from the data [78]. Although the
aim of these methods is prediction, the study of biomarkers can also give an insight to molecular
processes behind the phenotype [53].
2.3.1 Identiﬁcation of putative genetic variation behind phenotype
Traditionally, medical genetics has aimed to identify chromosomal regions that are associated wiht
inheritance of a phenotype in families [79]. The goal has usually been to target very rare and striking
phenotypes, such as Mendelian diseases, that presumably are caused by rare, high penetrance genetic
variants, i.e., variants that cause a disease in a high proportion of carriers [80].
Another statistical approach is a large population study, in which an association between genetic
variants and phenotype is sought for. These studies use the common variant  common disease
model, which assumes common, low-penetrance variants to cause subtle phenotypes, such as cancer
predisposition [81, 82]. Since many phenotypes do not fall directly to these categories [82], a plethora
of other computational methods, which are reviewed later in this section, target phenotypes in between
these inheritance models.
Statistical linkage and association analysis The linkage analysis tests whether a genetic locus
and an inherited phenotype are segregating together in a pedigree [83]. Figure 2.7 shows the genetic
basis of this analysis where the closest measured marker correlates the most with the causative allele
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[80]. A statistical linkage analysis uses families to identify high penetrance genetic variants [84]. This
analysis requires estimations of inheritance of alleles, penetrance and allele frequencies [79]. The
linkage analysis can include either aﬀected sibling pairs or families with multiple aﬀected individuals
[84, 80]. The linkage analysis requires the genotypes in the family to be informative in or near to the
causative variant locus, i.e., to show heterozygosity in the pedigree to distinguish the maternally and
paternally inherited alleles [84]. The linkage analysis is highly powerful in locating a genetic locus
carrying the causative allele. However, the use of the linkage analysis is restricted to limited research
settings where information on pedigrees, number of individuals and families, inheritance model, and
allele frequencies is available. In practice, all this information is only rarely known.
A genome-wide association study (GWAS) for common variant  common disease model tests
statistical association with SNPs' allele frequencies and a phenotype, such as a disease, from thousands
of samples [81, 57]. When this test is done genome-wide, it results in hundreds of thousands of tests,
which requires a very large set of samples for enough statistical power [81, 57]. The phenotype may
be discrete or continuous, which aﬀects selection of the statistical test [81]. However, an association
test may ﬁnd a false positive variant because of a confounding eﬀect such as population stratiﬁcation,
which is also emphasized when the number of samples increases [84, 81].
Identity-by-descent analysis A phenotype is not necessarily caused by a common genetic variant
but by multiple rare variants, which requires analyzing shared ancestry [81]. Identical chromosomal
regions between individuals may be inherited from a relatively recent common ancestor [85, 86] or they
may emerge due to a random event, these regions are called identity-by-descent (IBD) or identity-by-
state (IBS), respectively. Figure 2.7 illustrates how chromosomal segments are broken in a generation.
The causative allele is usually surrounded by a longer stretch of DNA, which is the IBD region between
individuals.
The rare causative variants can be enriched in families [82], and the IBD regions in populations
can be used in genetic analysis [55, 82]. The IBD analysis assumes that individuals who share a
rare, phenotype-causing, variant inherited from a common ancestor also share a longer chromosomal
region surrounding the causative variant [81, 85, 86]. The analysis identiﬁes these IBD regions between
pairs of individuals taking into account the genome-wide relatedness between this pair [81], estimated
haplotype sharing [85], or identical haplotype matching [86]. To ﬁnd the locus harboring the causative
variant behind the phenotype, the IBD sharing between cases can be compared to IBD sharing between
controls [81, 85]. Homozygosity detection can also be used to identify IBD. It is especially useful when
studying a phenotype that shows recessive mode of inheritance [81, 87].
Haplotype analysis A general IBD analysis can be extended to investigate haplotypes. A haplo-
type is a chromosomal segment that is inherited in a pedigree or in a population without recombination[19].
In population level, haplotypes are observed as haplotype blocks that have reduced haplotype diversity
or high LD, depending on deﬁnition [88]. Examples of haplotypes are visualized in Figure 2.7.
As genome is inherited in haplotypes, it is organized accordingly [89, 90, 91, 55]. Recent muta-
tions are expected to be inherited in a speciﬁc haplotype [81, 90, 92]. However, single-marker tests
do not capture the eﬀect of rare variants, especially with a small number of samples [93, 94, 55].
Thus, haplotype-based analysis has been expected to increase statistical power due to reduction in
dimensionality [90, 93]. Therefore, various eﬀorts have been implemented to account for haplotypes
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Figure 2.7: The genetic analysis is based on the genetic linkage between loci. The recombination of
maternal and paternal chromosomes produces a new combination of the chromosome. The up-most
image shows the original chromosomes of a parent. In the middle, the chromosomes are recombined to
produce two copies that can be transmitted to the oﬀspring. Here the uppercase letters show genetic
markers passed from the father and lowercase letters those passed from the mother. The causative
allele is segregating with the marker A, which is more often inherited with B than with marker C. This
information is used in linkage analysis. The statistical association analysis, instead, ﬁnds association
between marker A and the phenotype. The IBD analysis targets to identify the chromosomal segment
carrying marker A from multiple individuals with common ancestry. Haplotype analysis identiﬁes the
paternal haplotype with marker A based on haplotype with markers A and B inherited to oﬀspring.
This ﬁgure is published by Wellcome Trust websites under Creative Commons Attribution 2.0 UK
license [link to ﬁle 20.11.2012, http://genome.wellcome.ac.uk/doc_WTD020778.html].
in statistical association analyses [81, 89, 92, 91, 94, 95, 96, 97, 98]. Typically those methods identify
haplotypes and test for their statistical association with the phenotype.
The haplotype identiﬁcation approaches vary, as the haplotypes are identiﬁed using various sliding
window approaches [99, 100, 97], based on haplotype blocks [93], by identifying haplotype clusters
[98], building a cladistic model [92] and taking the haplotypes that are divided to multiple loci [91, 95].
Often haplotype information is not available in the genotypes, and the analysis requires haplotype
estimation, i.e., a phasing step [57]. The purpose of phasing is to resolve how alleles are inherited
from a father and a mother. Haplotype detections use genotype data that is either with phasing
[92, 97, 98] or without phasing [91, 93, 94, 95, 96, 99]. The haplotype analysis methods are targeted
to genome-wide analysis [93, 98, 99] or to investigate limited chromosomal areas [96, 100].
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Figure 2.8: Box plot visualization of gene expression measurements of a gene ankyrin repeat and
SOCS box containing 9 gene (ASB9 ) from samples in diﬀerent cell lines: human microvascular en-
dothelial cell line (HMEC), telomerase immortalized microvascular endothelial cell line (TIME), blood
endothelial cells (BEC), and lymphatic endothelial cells (LEC) from the normalized gene expression
data used in Publication III. The average gene expression of BEC and TIME samples is higher
compared to average gene expression of HMEC and LEC samples. The gene expression analysis
identiﬁes genes where such diﬀerences exist.
2.3.2 Mining of gene expression diﬀerences between phenotypes
The analysis of gene expression data usually detects genes that have diﬀerential expression between
samples, or studies the similarity of gene expression between genes [63]. The whole-genome gene
expression analysis usually ﬁnds a small set of genes to be diﬀerently expressed between the samples
while the majority of the genes do not show signiﬁcant diﬀerences [72].
Usually a gene expression study includes gene expression measurements from several technical
or biological replicates under one or multiple types of conditions from which the gene expression
patterns are quantiﬁed. Typically, normalized gene expression values are used in logarithmic scale to
ease computation and make gene expression diﬀerences independent from the level of gene expression
[63].
Figure 2.8 shows distribution from the gene expression measurements of one diﬀerentially regulated
gene (multiple hypothesis corrected p-value < 0.05), where the average of the gene expression is
signiﬁcantly diﬀerent between two of the sample groups although the expression values may vary
within the sample groups. The sample groups in Figure 2.8 are blood endothelial cells (BEC),
human microvascular endothelial cell line (HMEC), lymphatic endothelial cells (LEC), and telomerase
immortalized microvascular endothelial cell line (TIME). These data were used in Publication III.
Usually, gene expression analysis aims to identify genes that show these kind of gene expression
distributions.
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The diﬀerential expression, which is also stated as up- or downregulation, can be tested using
a statistical test of diﬀerence between expression distributions [63, 70]. The diﬀerentially expressed
genes can be identiﬁed using a p-value threshold, or simply by calculating a fold change of gene
expression between samples [63, 70]. These values can be used jointly or separately to evaluate gene
expression diﬀerences. A statistical test, like Student's t-test, gives a conﬁdence value, i.e., a p-value,
to reject the null hypothesis, which is interpreted as conﬁdence for the true gene expression diﬀerence
[73]. The fold change value is used only to rank the genes and quantify the diﬀerence because it
does not include any information about variance of the gene expression [73]. At simplest, the gene
expression analysis results a set of diﬀerentially regulated genes.
The similarity between gene expression proﬁles can be analyzed using supervised [63] and unsu-
pervised (clustering) [63, 77, 73] learning approaches. Also, an enrichment of pre-deﬁned gene classes
can be tested to interpret the results [73]. These classes can be chosen for each study, but often gene
ontology [101] classes are used [73].
The gene expression analysis results may contain false positives and false negatives [73]. A golden
standard has been that the signiﬁcant genes are validated using independent biological samples and
the same experimental settings to rule out reporting false positives, but false negatives are rarely
evaluated in an independent study [73].
2.3.3 Use of existing biological knowledge
Molecular measurements and the subsequent analysis alone are rarely enough to understand the
molecular mechanisms behind phenotypes. Instead, the results are interpreted or the study is designed
in the light of existing knowledge. Here, biological databases are key resources. An essential feature
of these databases is that they can be accessed automatically, which allows systematic use of all
information stored in these databases. Furthermore, this enables the use of computational approaches
to modify the data and to integrate biological knowledge with study results [102, 103, 104, 105]. Often
integration aims to understand the ﬁndings of the analysis either based on gene annotations, for
example, characterizing aﬀected genes in breast cancer tumors [5], molecular functions, or molecular
networks [106, 5]. The existing knowledge can also generate new candidates for further analysis which
can be based on the molecular networks and functions [103].
Biological experiments and the subsequent analysis may produce such a large number of candidate
genes that downstream analysis and validation is not feasible for all of them [76]. Here, the protein-
protein interaction (PPI) or another functional relation can be used to infer which candidates are the
most relevant by using a functional link between a causal gene already identiﬁed and the candidate
gene [76]. However, one data source, such as PPI, is rarely enough to create a comprehensive context
for the candidate gene prioritization, thus multiple sources should be integrated [76]. Also, the
candidate gene prioritization can be executed backwards from knowledge to measurements, by using
existing biological knowledge to generate candidates to guide the design of biological experiments
[76].
Biological knowledge bases In this thesis, all computational resources that provide informa-
tion from multiple levels of molecular functions to support biomedical research are seen as biological
knowledge bases. They can be either traditional curated databases or tools to generate knowledge.
Table 1 shows a grouping of knowledge bases relevant for this work. The biological knowledge bases
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Table 1: The grouping of knowledge bases. The biological knowledge used in biomedical research
is stored into various centralized repositories. These repositories can be grouped into single muta-
tion eﬀect, chromosomal or protein annotations, systems biology, and systems biology meta server
resources.
Type of knowledge
base
Use of the
knowledge base
Examples of
knowledge bases and
computational
resources
Single mutation eﬀect
Prioritizing of ﬁndings,
creating hypotheses,
selecting tagging SNPs,
listing known
mutations
Sift [107], SNPs3D
[108], PolyPhen [109],
Cosmic [110]
Gene and protein
information
Interpretation of
ﬁndings, reference
knowledge
Ensembl [111], Entrez
[112], InterProt [113],
HapMap [55]
Systems biology
Interpret systems eﬀect
of the ﬁndings,
understand dynamics of
the system, predict new
candidates
KEGG [114] ,
Reactome [115], PINA
[116], GO [101]
Systems biology meta
servers
Integrate information,
computational
modeling of the system
Moksiskaan [103],
BioMine [102]
provide information about the eﬀect of single mutations or variations, chromosomal or protein anno-
tations, and biological systems. In addition, meta servers collect information from multiple sources
and integrate them into a knowledge base.
The single-mutation knowledge bases give information on whether variants potentially aﬀect gene
regulation or protein [117, 118]. They can also be used to generate a set of interesting variants for
instance to study segregating SNPs in a population [118]. In the case of diseases, the question is even
simpler: is the variant detrimental for the protein, thus preventing normal cell functions [117]? This
single-molecule information can be predicted [118, 117], for example, using sequence conservation
[107] or a larger vector of molecular features [109, 119], or it can be veriﬁed by mutation-phenotype
consequence, such as in cancer [110].
Biomedical research uses chromosomal annotations to give a species-speciﬁc reference to the data.
Genome databases maintain the most recent annotations of the genomes of various species [112,
111]. From these databases one can ﬁnd the chromosomal coordinates of the genes, known variants,
transcripts, peptides, citations to original publications [112, 111], allele frequencies in populations
and population linkage structure [55]. In the study of gene products, proteins, information from the
research is stored into protein databases including annotations such as protein sequences, domains,
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or protein structure [113].
Studying individual genes or mutations follows the reductionistic paradigm where understanding of
the system should be achieved by studying its parts. However, systems biology aims to understand the
system as a whole, and in this work the existing knowledge of molecular interactions, i.e., molecular
networks, is essential [120]. The networks can be used to interpret the causal consequence of the
ﬁndings or predict new hypothesis.
The pathway, PPI, and molecular function databases can be seen as systems biology databases
[120, 121]. These databases have diﬀerent emphasis: pathway databases usually contain information
about molecular signaling transduction or other molecular pathways where information is conceptual-
ized to biologically deﬁned pathways and networks [120, 121]; PPI databases list veriﬁed or predicted
protein pairs that have physical interaction [120, 121]; and molecular function databases link molecular
functions and cellular locations with genes, to describe relationships among these concepts [120, 101].
Meta servers in systems biology integrate information from existing molecular network databases
[121, 103, 102]. These meta servers in systems biology also compile the data into a complete net-
work representation of this information [102, 103]. They also overcome the scattered nature of the
databases, as they combine information from multiple sources [121].
2.3.4 Creating predictions from gene expression data
The diﬀerentially expressed genes from gene expression analysis can be used directly as biomarkers
to discriminate phenotypes, although a more complex panel of gene expression signatures may be a
more eﬀective biomarker [48]. Classiﬁcation, or supervised learning, can capture complex features
in the data, and thus produce a powerful predictor for a phenotype [48]. Although classiﬁcation is
an integral part of gene expression analysis [73], it is also a very large ﬁeld in biomarker discovery
covering many computational methods [48, 122, 123, 124]. The goal of classiﬁcation analysis is to
ﬁnd the gene expression pattern and classiﬁer that yield the best prediction for the phenotype [78].
The technical modiﬁcations, such as probe mapping and normalization, in gene expression microarray
data processing may complicate creating a predictive classiﬁer [78], however, this may not be the case
in other gene expression measurement technologies.
Computational classiﬁcation by supervised learning The computational classiﬁcation uses
training data where each gene expression signature is labeled according to the phenotype, such as
disease and healthy [78]. The classiﬁer deﬁnes a mathematical function for producing the classiﬁcation
based on the data, and, from the training data, it learns parameter values that best produce the
phenotype labels [78]. The outcome of this process is a classiﬁer that can be applied to new datasets
to predict previously unknown phenotype labels [78, 125].
Classiﬁcation is often impaired due to a large number of genes in the gene expression signatures
[78]. The learning typically includes feature selection, which is gene selection in the case of gene
expression data, to produce a set of genes used in the classiﬁcation [48, 78, 125, 126]. The feature
selection aims to select a subset of the original dataset and, unlike other, more general dimensionality
reduction methods, does not transform original values [126]. When the number of genes in the dataset
is high, as it usually is in gene expression microarrays, the feature selection requires specialized
algorithms [48, 78, 126]. However, in a small set of genes, it is possible to go through all available
gene expression combinations to ﬁnd the optimal set of genes for classiﬁcation.
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Table 3: Hypothetical example of a classiﬁcation to predict a disease. The confusion matrix shows the
quantity of correctly classiﬁed true positives (TP) and true negatives (TN), and incorrectly classiﬁed
false negatives (FN) and false positives (FP).
Disease Healthy
Predicted disease 10 2
Correctly
classiﬁed
TP
Incorrectly
classiﬁed
FP
Predicted healthy 3 12
Incorrectly
classiﬁed
FN
Correctly
classiﬁed
TN
Some widely used classiﬁcation functions deploy diﬀerent approaches to achieve the classiﬁcation.
One powerful method to classify instances is artiﬁcial neural networks (ANN) [127]. They are com-
prised of neurons and weighted connections between them, where each neuron deﬁnes an activation
function to calculate an output that is fed to the next neuron, and the network output is the classiﬁca-
tion for each instance [78, 125, 127]. The ANNs have many variations; one type of ANN is multilayer
perceptron (MLP), which is a feed-forward model where neurons are organized into layers, and each
layer feeds the output to the next layer of neurons [127]. Each neuron implements a non-linear acti-
vation function that is a combination of all the inputs [127]. The parameter values learned from the
data are the weights for the combination function for each input [127]. Finally, learning is achieved
by minimizing an error function [127].
Some other classiﬁcation functions that have been used in biomedical analysis are: Instance based
learning, where the prediction is based on similarity with known instances, and similarity metrics are
typically distance metrics, such as Euclidean distance [78, 125]. Linear discriminants deﬁne a linear
function that returns a value from gene expressions, which is used to divide instances to classes based
on a threshold [78]. Statistical classiﬁers use a probability model for classiﬁcation of the instances
[125]. Support vector machines (SVM) use a hyperplane that maximizes the distance to instances
of classes in multi-dimensional space [78, 125]. Logic based methods [125], like decision trees, create
a set of rules, that can be in tree structure, for classiﬁcation [78, 125]. If the data has multiple
phenotype classes, these classiﬁcation methods may require some adjustments [125, 78].
Biomedical research has multiple examples of biomarker discovery using computational classiﬁca-
tion. The breast cancer prognosis predictor from 70 gene expression signatures [48] is a well-known
example. It uses wrapper feature selection that selects genes using rank-based ﬁltering while evalu-
ating the classiﬁcation along the gene selection [126]. Another study identiﬁed a 74 gene signature
to predict breast cancer patients' response to chemoterapy [122]. This study used a specialized al-
gorithm for gene selection and compared multiple classiﬁers to ﬁnd the best performing classiﬁer for
the treatment outcome [122].
Classiﬁer evaluation Classiﬁers are evaluated by using a validation dataset, and the evaluation
is based on correctly and incorrectly classiﬁed instances [78, 125]. The validation dataset can be an
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Figure 2.9: An example of four hypothetical receiver operating characteristics (ROC) curves and their
corresponding area under curve (AUC) values. Black curve with AUC value 0.5 presents poor classiﬁer
where in average each true positive classiﬁcation produces another false positive classiﬁcation. Red
curve with AUC value 0.93 is produced for most accurate classiﬁer in this example.
independent dataset or cross-validation can be used [78, 125]. The independent training and validation
datasets can be constructed by splitting the original dataset into two sub-datasets [125, 78]. In cross-
validation, the dataset is divided into subsets that each are used as the validation dataset in turn,
and the statistics from these validations estimate the accuracy of the classiﬁer built from the whole
dataset [78].
The validation produces a so called confusion matrix that shows how many times classiﬁcation was
correct. In practice, the confusion matrix is a table where the columns are real classes and the rows
are predicted classes, and it can be used for visualization and as a source for performance statistics.
Table 3 shows an example of a hypothetical confusion matrix.
A typical metric for classiﬁcation accuracy is the receiver operator characteristic (ROC) curve,
which is a graphical presentation of classiﬁcation sensitivity and speciﬁcity over diﬀerent classiﬁcation
parameter stringencies where, for each class, true-positive rate is plotted against false-positive rate
[128]. Area under curve (AUC) is the value that describes the size of the area that the curve occupies
from the graph [128], and it is used to give a score for a ROC curve. Figure 2.9 shows an example of
four hypothetical ROC curves and their corresponding AUC values. When evaluating a ROC curve,
random guess produces 0.5 AUC value and perfect classiﬁcation produces the value 1.
One somewhat rarely used metrics is the κ-value, which describes how much the agreement on
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classiﬁcation results diﬀers from random guessing between diﬀerent raters [129]. This concept can
be extended to evaluate the agreement between true and predicted classes, as is done in the data
mining software, Weka [130]. There, κ-statistics are calculated from the values in a confusion matrix
as (Po−Pc)(1−Pc) , where Po is the observed agreement and Pc is the agreement that would be achieved by
chance.
Classiﬁcation has also a risk of overﬁtting, which means that, although generated classiﬁer pro-
duces correct predictions, it cannot be generalized beyond the training data [73, 78]. The risk becomes
even more prevalent when a complex function with multiple parameters is trained [78].
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The research in this thesis aimed to create computational methods for ﬁnding molecular features
contributing to phenotypes on multiple levels of biomedical research. These levels include genes in
the same functional context, inherited phenotypes, plastic cell type speciﬁc phenotypes and predictive
gene expression signatures.
Publication I Cancer evolves from aberrant molecular signaling, therefore, systems level view
of molecules behind the phenotype is needed. Publication I presents a meta server (CANGES)
that integrates information from multiple biological knowledge bases [114, 115, 116, 111, 55, 107, 108,
131, 109] and creates hypotheses for understanding the molecular basis of the phenotype. CANGES
also suggests new SNP candidates that can be tested experimentally by either directly genotyping or
using linkage with the tagging SNPs. Publication I demonstrates the use of this approach in tp53
network and in candidate gene generation for survival analysis in glioblastoma multiforme (GBM).
Publication II The analysis of phenotypes in rare variant  moderate penetrance assumption
usually cannot be done using traditional statistical methods. Publication II presents an analysis
method (Haplous) that uses shared haplotypes to identify IBD regions from multiple individuals
having a recent common ancestor. Also, in Publication II performance of Haplous is tested in
various settings with simulated data and with data that has haplotype phasing errors. It is also used
to analyze shared haplotypes in family members aﬀected by lymphoma in multiple Finnish families.
Publication III The cell type speciﬁc phenotype is determined by altered gene expression.
The identiﬁcation of the diﬀerentially expressed genes between cell types is often hampered by a
limited number of samples. Publication III pools multiple samples from multiple gene expression
platforms to analyze molecular determinants behind blood endothelial cells (BECs) and lymphatic
endothelial cells (LECs). The approach identiﬁes novel markers that are validated. This approach
can be extended to any other tissue types.
Publication IV The studies that identify molecular determinants behind phenotype rarely
result in one marker but a list of molecules that may have combinatorial eﬀects on the phenotype.
Publication IV shows how a predictive gene expression signature of multiple genes can be identiﬁed
from the expression data. In this publication we apply computational classiﬁcation to acquire the
molecular signature that best predicts recovery from cow's milk allergy (CMA).
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The overall goal of this work is to develop computational methods, whose utility can be demonstrated
using SNP and gene expression datasets. The phenotypes selected to the analysis manifest on diﬀerent
organismal levels: cancer, whose cellular regulation has changed from the normal, inherited cancer
predisposition, cell type diﬀerences, and transient cow's milk allergy. The computational methods
developed aim to discover various molecular features behind these phenotypes and also detect new
biomarkers. This section gives an overall description of the materials and methods. The details for
technologies and parameters can be found from the original publications.
4.1 Data
The material used in this study consists of measurements of genetic variation and gene expression.
Table 4 shows a summary of types of data used in the publications. The measurements of genetic
variation are from high-throughput SNP technologies, and the gene expression measurements use
both whole genome approach and more targeted expression data from selected genes. This section
gives an overview of the data. The details can be found in the original publications.
4.1.1 The genome-wide SNP array data
Publication I and Publication II used genome-wide SNP microarray data. The data were used
to estimate the eﬀect of inherited genotypes to the phenotype.
To show the utility of integrating information from biological knowledge bases to enrich the genetic
analysis, we used genome-wide SNP array data from cancer patients in Publication I. The Cancer
Genome Atlas (TCGA) database provides clinical information and high-throughput measurements
from cancer patients and their tumors from heterogeneous measurement technologies. The ﬁrst launch
of the TCGA database consisted of glioblastoma multiforme (GBM) patients and a few unaﬀected
seizure patients as controls [132]. GBM is a type of grade IV tumor that originates from the glial
tissue in the brain. The patients show very poor survival with median time of 12 months [132]. For
Publication I, we used genome-wide SNP data derived from 209 GBM patients' blood samples
from the TCGA database. The SNPs were genotyped with 550K SNP microarray.
In Publication II, we used genotypes from three Finnish families to test our approach to identify
shared haplotypes from individuals having a recent common ancestor. These families may have
a lymphoma predisposition, since multiple individuals in these families are aﬀected with several
diﬀerent lymphoma subtypes. The lymphoma subtypes in this analysis were: nodular lymphocyte
predominant Hodgkin lymphoma (NLPHL), T-cell/histiocyte rich B-cell lymphoma (TCRBCL), non-
Hodgkin lymphoma (NHL), and classical Hodgkin lymphoma (cHL).
We had the DNA from blood of nine aﬀected family members and, when possible, their parents.
Also, DNA from the children and siblings of deceased lymphoma-aﬀected family members was used.
This resulted in 29 samples. All the samples from the lymphoma families were genotyped with
370K SNP microarray. Haplotype phase for these samples was predicted based on the pedigree using
MERLIN [83].
To control for typical haplotypes in the Finnish population, we included genotypes from 250
unaﬀected Finnish individuals from the Nordic Center of Excellence in disease genetics (NCoEDG)
22
4 Materials and methods
Table 4: List of data types used in publications. Publication I and Publication II used data
from SNP microarray measurement technology. The data set in Publication I used the genotypes
of glioblastoma multiforme (GBM) patients measured from germline. Publication II used germline
genotypes from Finnish lymphoma families, unaﬀected controls, and family trios from a HapMap
database. Publication III integrated three diﬀerent Aﬀymetrix gene expression microarray plat-
forms from a Gene Expression Omnibus (GEO) database. Publication IV used gene expression
data from 12 genes measured by RT-qPCR.
Publication Measurement technology Description
Publication I SNP microarray SNP genotypes of GBM
patients measured from
germline
Publication II SNP microarray SNP genotypes from germline
of lymphoma families and
unaﬀected controls
SNP microarray SNP genotypes of family trios
from HapMap database
Publication III Gene expression microarray Three diﬀerent Aﬀymetrix
platforms from GEO
database
Publication IV RT-qPCR Gene expression of 12 genes
control database [http://www.ncoedg.org/]. The haplotype phase of these controls was predicted
using HaploRec [133].
The HapMap database has genotypes from parent oﬀspring trios whose haplotype phase can be
determined based on the pedigree [55]. As the haplotype phasing may produce uncertainty to the
data, we used phase-known SNP microarray data from HapMap phase 3 database using European
population (CEU) and chromosome 12 [55]. The 29 samples from these trios were used as a reference
in Publication II to study the eﬀects of haplotype phasing in the results. The haplotype phase was
estimated using HaploRec [133].
4.1.2 The pooled genome-wide gene expression data
The genome-wide gene expression data was used in Publication III where we identiﬁed new gene
expression markers that determine the phenotype in cell types. We downloaded the raw gene expres-
sion data of 33 BEC samples and 14 LEC samples from public Genome Expression Omnibus (GEO)
database [34]. These samples are from three diﬀerent Aﬀymetrix platforms: Human Genome U133
Plus 2.0 Array (14 BECs, 10 LECs), Human Exon 1.0 ST Array (7 BECs, 4 LECs), and Human
Genome U133A 2.0 Array (12 BECs).
Prior to the study in Publication III, 189 candidate samples from relevant studies were collected
for the analysis from 18 diﬀerent gene expression platforms. 112 samples were BECs, 40 LECs, and
37 samples were unsorted microvascular cells. The unsorted microvascular cells were discarded at the
beginning since they could not have been included to comparison of BEC and LEC cell types. After
discarding unsorted microvascular cells, the data had 17 diﬀerent gene expression platforms. Other
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candidate samples, except the 47 samples from Aﬀymetrix gene expression platforms, were discarded
because of various technical problems in integration of the samples.
4.1.3 The RT-qPCR data
The gene expression data from 12 genes used in Publication IV were measured from mononuclear
cells of peripheral blood from 44 children after βlactoglobulin stimulation in vitro. 13 of these
children were non-atopic healthy controls; 16 children had had CMA, but they had achieved the
tolerance by the age of three; 15 children had persistent CMA. The gene expression was quantiﬁed
with the RT-qPCR method. The genes selected for study were T-cell markers T-bet, GATA-3, IFN-γ,
CTLA4, IL-10, IL-16, TGF-β, FoxP3, Nfat-C2, TIM3, TIM4, and STIM-1.
4.2 Bioinformatics workﬂow execution
All methods presented in this thesis are implemented as pipelines that can be executed using an
Anduril bioinformatics workﬂow engine [105]. Anduril is component-based: each analysis step is
implemented as a component that can be connected to each other using their inputs and outputs.
These inputs and outputs are usually in ﬁles on a computer disc, and Anduril takes care of passing
the data from one component to another. Also, intermediate results from each component are stored.
Anduril transforms the pipeline into a network presentation and evaluates the dependencies between
each component. Information about the component dependencies are used to parallelize the execution
as the independent components can be executed concurrently and, in the case of re-execution, only
components that have modiﬁcations are executed and results from others can be used without re-
execution. As the dependencies are clear, modiﬁcations and maintenance of analysis pipelines are
easy. The pipeline itself is constructed using special language, AndurilScript, which can be used as
description of the analysis.
4.3 Data integration method for systems biology
Publication I introduces a method for creating hypotheses and for interpreting results using existing
knowledge from systems biology databases, gene databases, and single-molecule resources. This
method, CANGES, is essentially a meta server that integrates information from multiple biological
resources. The schematic representation of the CANGES workﬂow and technologies is shown in
Figure 4.1. CANGES identiﬁes focal genes, i.e., candidate genes for the causative molecules behind
the phenotype. For the focal genes, CANGES collects central SNPs, which are SNPs in the focal
gene's chromosomal region. For these SNPs, CANGES collects many relevant annotations into one
repository for later use, and creates a list of markers that are in LD with the central SNPs. Finally,
CANGES fetches predictions on the coding SNP's impact.
CANGES assumes that the putative impact of focal genes to a given phenotype is deﬁned by the
same function that the already known genes have. These genes are used in CANGES as query genes
to seed the focal gene search. In practice, the focal gene is in the same pathway or having a PPI with
the query gene's protein product. The focal genes are collected from pathway databases KEGG [114]
and Reactome [115], and from the PPI database PINA [116], using the query gene as a search seed.
The focal genes are annotated for their central SNP from the Ensembl database [111], and the
markers that are in LD with those central SNPs are collected from the HapMap database [55] using
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Figure 4.1: The CANGES data integration workﬂow consists of three modules that each access
diﬀerent databases to collect the data. The octagons are the modules, rectangles are data accessions,
circles are data ﬁles, and the arrows represent the data ﬂow in the system. This diagram shows the
knowledge bases that are used, and the technology for accession is denoted with green font. SNP
Module requires the collection of information from the Ensembl database using diﬀerent queries and
connection types.
an appropriate population. Ensembl also provides annotations of the central SNP's function and their
chromosomal region.
Finally, the SNPs falling into coding regions are evaluated for their function. For this, CANGES
uses the SNP function prediction resources SIFT [107], SNPs3D [108], PolyPhen [131], and PolyPhen2
[109]. These SNP function predictors give an estimate for damaging eﬀects of the coding SNPs to the
protein. SIFT relies on peptide sequence conservation [107] and SNPs3D, PolyPhen, and PolyPhen2
classify amino acid changes based on a set of molecular features [108, 131, 109].
CANGES is implemented on the Anduril bioinformatics workﬂow engine [105], and, when possible,
it uses the public programming interfaces provided by the databases, including BioMart query tool
[134].
We applied CANGES on two research settings: we characterized the focal genes from the tp53
molecular signaling network and created a list of the central SNPs; and we generated a set of central
SNPs in GBM, which were analyzed using high throughput genotype data. The central SNPs in
GBM were identiﬁed using six putative GBM predisposition genes [135] as query genes: telomerase
reverse transcriptase (TERT ), cyclin-dependent kinase inhibitor 2B (CDKN2B), cyclin-dependent
kinase inhibitor 2A (CDKN2A), regulator of telomere elongation helicase 1 (RTEL1 ), coiled-coil do-
main containing 26 (CCDC26 ) and pleckstrin homology-like domain, family B, member 1 (PHLDB1 )
[135].
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4.4 Rule-based haplotype analysis from genome-wide data
We developed a rule-based computational method, Haplous, to identify shared haplotypes (SH) from
distantly related individuals (Publication II). Haplous uses rules to identify and ﬁlter SHs that
are seen in cases showing the phenotype, but which are almost absent in unaﬀected controls. The
rules used in Haplous are expert deﬁned and implement a natural deduction of what makes a SH
interesting.
Haplous uses phased genotype data that can be bi-allelic SNPs or multi-allelic markers. It identiﬁes
the SH by comparing each sample pair using a ﬁxed-size sliding window that allows mismatches in the
SHs. The window size is determined by markers in a window, although Haplous has support for using
base pairs as the metric. Then the SHs between sample pairs are collapsed into one data structure,
which allows identifying with whom each sample shares the haplotype. The detailed algorithms
are provided in Publication II, but Figure 4.2 visualizes the process of SH identiﬁcation and the
output it creates. From these SH data, Haplous ﬁlters interesting SHs using rules. These rules take
into account homozygosity and heterozygosity and allow deﬁning the frequency in which the SH is
seen in cases and in controls. It also ﬁlters SHs based on informativeness that is calculated from
allele frequencies. Finally, SHs are given a score according to their length and sharing in cases, and
the score is penalized if it is shared by controls. Haplous also doubles the score if SH is shared in
a homozygous region. Haplous identiﬁes loci where multiple individuals share the same haplotype,
which is more interesting than ﬁnding multiple individuals to share diﬀerent haplotypes.
We ﬁrst compare the Haplous results in a setting where there are no switch errors from the phasing
step in the data and then when the haplotype phase estimation has produced switch errors. For this
we use samples in the HapMap [55] database. Then we apply Haplous to Finnish lymphoma families
and identify chromosomal regions shared by multiple individuals. Finally, we simulate a dataset that
corresponds to our study with lymphoma families and compare it with an existing method [85]. We
also test the eﬀects of false assumptions to the results by using inappropriate parameter values.
4.5 Pooling heterogeneous studies to compare cell types
In Publication III we use gene expression analysis to identify diﬀerentially expressed genes between
phenotypes. To acquire a large set of samples for analysis, we increase the number of available
samples to 47 by pooling samples from three genome-wide gene expression platforms from a public
gene expression database GEO [34].
For pooling the samples, we created an Anduril pipeline for data processing. First the pipeline
takes a list of GEO sample identiﬁers as an input and downloads raw gene expression data, and
when the raw values are not available, downloads preprocessed data. An output from the download
is a database that consists of gene expression signals of each sample in separate ﬁles, annotations of
data location in GEO server, information about biological source of specimens, and some technical
information. This database also contains information about gene expression measurement platform
types. After download, the processing pipeline allows manual intervention to exclude gene expression
platforms from further processing by setting a ﬂag to the database. For preprocessing the pipeline
transforms raw gene expression signals into gene expression values, normalizes samples within each
platform separately with user-deﬁned normalization methods, and annotates each gene with their
Ensembl gene identiﬁers [111]. As a ﬁnal step of preprocessing, this pipeline produces a quality
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Figure 4.2: Visualization of the identiﬁcation of shared haplotypes and output from this process in
Haplous. Two samples in this visualization are denoted by symbols S1 and S2. For both samples,
Haplous takes the phased chromosomes as input, and slides a ﬁxed-size window over all pairs of
available chromosomes. Alleles that are the same within this window constitute a shared haplotype
(SH). SHs are visualized with colores (green, red, blue). As SHs between chromosomes are overlapping
(for example the green and red SHs in loci from three to ten) they are collapsed into a specialized
data structure visualized on the right, using corresponding colors. This structure shows which of the
original chromosomes share the SH and allows easy lookup of homozygous and heterozygous SHs.
control report with visualizations of data including box plot, cumulative distribution, and hierarchical
clustering for each used normalization method. This report can be used to select the preprocessed
datasets to ﬁnal analysis. After these steps all samples are integrated into one expression matrix
using the gene identiﬁers to map gene expression values between samples. Then follows two ﬁltering
steps in which all samples that have missing values in more than user-deﬁned percentage of genes are
removed, and all genes that have missing values in more than the user-deﬁned percentage of samples
are removed. Finally the pipeline normalizes all samples with user-deﬁned normalization methods
to adjust all samples to the same scale. The actual gene expression analysis pipeline is only semi-
automated since statistical tests and fold change calculations require several deﬁnitions of sample
groups used in comparisons.
The 152 BEC and LEC candidate samples originally intended for the analysis had to be reduced
into 47 samples because of the following challenges: 51 samples did not have raw gene expression
signals available and they have been preprocessed using unknown protocols. Six samples were copy
number variation measurements and could not be used. Automatic reading of the expression signals
was not possible from four samples produced with non-commercial platforms. Furthermore, technical
production of non-commercial platforms uses unknown and heterogeneous protocols, thus we decided
not to create separate readers for them. One Aﬀymetrix platform was represented with only one
sample, thus that sample was also excluded. Finally, the average correlation between platforms was
poor, except for the selected Aﬀymetrix platforms where it was ≥ 0.68.
Unlike the typical gene expression studies, this approach requires two normalization steps to
acquire comparable samples. The ﬁrst step uses the platform dependent analysis method, which
is necessary to combine the probe set expressions to gene expressions. Then all the samples are
normalized again to enable inter-platform comparison. This pooled expression dataset can then be
tested for diﬀerentially expressed genes. In this study, we used Student's two-tailed t-test combined
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with fold change to ﬁnd diﬀerentially expressed genes. We also visualized the ﬁndings with box
plots. In addition, we performed the same analysis using a subset of samples, 14 BECs and 10
LECs measured with Aﬀymetrix Human Genome U133 Plus 2.0 Array gene expression microarray
technology.
4.6 Biomarker prediction using machine learning
In Publication IV we present an application for identifying biomarkers from gene expression data.
For this biomarker discovery, we use machine learning technique, multilayer perceptron neural network
(MLP), which is a type of ANN. We use an implementation in a Weka data mining software [130]. In
MLP the neurons are organized in layers that process the information and feed it to the neurons on the
next layer. The ﬁrst layer is an input layer, the last is an output layer, and they are connected with
at least one hidden layer. Here we allowed Weka to automatically organize a MLP. This organization
has one input neuron for each gene used in the classiﬁcation, one output neuron for each three classes
and number of genes+number of classes2 neurons in one hidden layer. We choose the optimal set of markers
by testing all 4,095 marker combinations from the 12 genes. For each combination, we trained and
evaluated a classiﬁer for three phenotype groups. The optimal classiﬁer was chosen using the confusion
matrix, AUC value and κ-statistics.
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The result of this work is a set of computational approaches for analyzing the molecular background of
phenotypes. Sometimes molecular proﬁle in phenotypes can not be described with only one approach;
often a multi-level analysis from genetics to gene expression is needed. Ultimately, this analysis can
lead to more comprehensive understanding of molecular entities behind phenotypes, and, in medicine,
improved screening, diagnosis and treatments. The work done for this thesis provides a database
integration method to identify candidate genes and SNPs, presents a rule-based haplotype analysis
to study rare familial phenotypes, shows how pooling of data from gene expression studies can create
new insight on cell types, and shows that candidate genes can be compiled into classiﬁers that predict
phenotypes.
5.1 Using information from databases to create novel hypotheses for molecular
determinants behind cancer
In comparison to normal tissues, cancer is characterized by altered molecular signaling that allows
cancer cells to multiply uncontrollably [37]. The widely studied tp53 signaling network is a funda-
mental example of altered molecular signaling driving cancer [37, 41]. It is not only that tp53 itself
acquires mutations, but other genes contributing to the same signaling network produce the same
cancer phenotype when their function is altered [41]. One recent example of a systems level eﬀect is
an activated epidermal growth factor receptor (EGFR) signaling in a colorectal cancer cell line, that
makes the treatment targeted to mutated v-raf murine sarcoma viral oncogene homolog B1 (BRAF )
(V600E) ineﬀective [136]. The same treatment in melanoma is highly eﬀective [137], probably because
melanoma is mostly missing the EGFR signaling that acts parallel with BRAF [136]. Understanding
such molecular signaling networks allows pinpointing molecules that are putative drivers of cancer,
thus being lucrative targets for treatments or diagnostic biomarkers.
Publication I presents a metaserver, CANGES, that integrates information from multiple bi-
ological knowledge bases to generate hypotheses from the molecular functions behind a phenotype.
CANGES can be used in cases where systems level molecular functions are the main interest, such
as in cancer. Thus in Publication I, we show the beneﬁts of CANGES in two case studies. In
the ﬁrst case study, we used a known driver gene behind cancer, tp53, as a query gene to produce
a list of focal genes in breast cancer. This query produced 1,914 focal genes from the KEGG [114],
Reactome [115], and PINA [116] databases. For these focal genes, we identiﬁed 47,163 central SNPs
from the Ensembl database [111] and 3,465 tag-SNPs from HapMap European population (CEU) [55].
Then we predicted the impact of coding SNPs to the protein using four prediction tools: SIFT [107],
SNPs3D [108], PolyPhen [131], and PolyPhen2 [109]. These four methods gave the same prediction
of detrimental eﬀects for 158 SNPs.
In the second case study, we identiﬁed focal genes for GBM genes TERT, CDKN2B and CDKN2A
identiﬁed by a previous study [135]. The initial list of query genes included also RTEL1, CCDC26 and
PHLDB1, but they were not in the pathway or PPI databases. For GBM, CANGES returned 1,346
focal genes, which had 33,428 central SNPs that were tagged by 2,657 SNPs in HapMap European
population (CEU). From these 35,622 SNPs, 1,888 were in the TCGA [132] genome-wide SNP mi-
croarray. For those SNPs we evaluated their survival eﬀect. The most signiﬁcant survival associated
SNP was a tagging SNP for 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR) gene,
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which has a PPI in PINA with CDKN2A that is in KEGG annotated to the tp53 pathway. Thus,
MTR is a novel candidate as a GBM driving gene. The largest eﬀect was in a tagging SNP for a gene
cyclin B1 (CCNB1 ) that is located downstream from tp53 in the tp53 signaling pathway in KEGG
annotations.
The implementation on Anduril bioinformatics workﬂow engine [105] allows easy maintenance of
the database integration and possibility for re-execution of the analysis of CANGES. Therefore, the
same queries were re-executed on 3.12.2012 to investigate whether the databases have accumulated
more information since the original publication.
Indeed, CANGES identiﬁed 3,688 focal genes for the tp53 network, which is a signiﬁcant increase
from the original 1,914 genes. The GBM query genes yielded a list of 3,710 focal genes, but these
genes were found only for query genes TERT, CDKN2B and CDKN2A. Thus, candidate genes RTEL1,
CCDC26 or PHLDB1 are still absent from these databases. Our ﬁrst analysis for Publication I
conﬁrmed that the biological knowledge bases were not complete. Although their information has
increased, as our newest analysis shows, a bias towards a subset of molecules still exists.
After the ﬁrst release, Ensembl transcript identiﬁers have been added to CANGES results, and
BioMart [134] has stopped supporting peptide changes, thus, these features have been removed. An
unfortunate update has been the removal of KEGG from CANGES because of licensing policies; in
year 2013 the KEGG programming interface changed, and eﬃcient usage of KEGG database is no
longer feasible. This change will require new implementations for CANGES. Possible substitutes for
KEGG are WikiPathways [30] or generating new queries using Moksiskaan [103]. Also, PolyPhen2
[109] has completely replaced PolyPhen [131].
Our results show that using systems level biological knowledge from multiple sources provides
valuable information for analysis. For instance, the geneMTR was not annotated to the tp53 pathway,
although it may have a role in the signaling through PPI in GBM. Also, the comprehensive p53
network with its central SNPs provides a landscape to investigate major molecular determinants
behind cancer cells. Although our case studies are from cancer, a similar approach can be used to
other interesting phenotypes whether they are diseases or cell type speciﬁc phenotypes. This approach
can be applied to generate putative genes or genetic variants to identify relevant biomarkers from
experimental measurements.
5.2 Computational method to detect shared trait-associated haplotypes derived
from a common ancestor
Publication II presents Haplous, an analysis method to identify haplotypes shared by multiple
individuals. Haplous identiﬁes those individuals who have shared haplotype in heterozygous and
homozygous conformations and corresponding chromosomal regions. Haplous uses ﬂexible rules that
can be adjusted based on the research question at hand. Many methods for identifying the genetic
variant behind a phenotype, whether they are based on single-variants or IBD regions, are based on
statistical signiﬁcance [85, 89, 81]. However, in many cases the phenotype itself or the samples that can
be collected are not suitable for statistical testing because of low statistical power [82]. Nevertheless,
these cases should also be analyzed carefully, as genetic variants have considerable contribution to
disease risk [82]. Therefore, Haplous is targeted to rare variant  moderate penetrance paradigm,
where the phenotype has a molecular determinant that is inherited from a recent ancestor and it
causes an incompletely penetrant phenotype. Haplous is a rule-based method to detect haplotype
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sharing in multiple individuals. Haplous does not require an exact hypothesis of an inheritance model.
To investigate the eﬀect of incorrect haplotype phasing to the SH identiﬁcation, we evaluated
SHs from phase-predicted samples against SHs from phase-known samples. From this evaluation
we calculated the true positive (TP) and false positive (FP) rates. This was done by reducing the
window size from 2,000 SNPs to 1 SNP, and allowing one mismatch in the window. The TP rate was
the number of SNPs that were included to SHs both in phase-known and phase-predicted datasets
compared to all TP SNPs and the false negative (FN) SNPs that were discovered only from the
phase-known dataset. The FP rate was quantiﬁed by the number of SNPs falsely included to SH
compared to the number of SNPs that are diﬀerent between samples. The window sizes from 30
to 100 produced a high ratio between TP and FP rates. The phasing accuracy depends on the
population at hand [138]. For instance, a population of African origins has more haplotype diversity,
thus a larger number of samples is needed to estimate haplotype phase correctly [138]. However, the
phasing accuracy and its eﬀect on the results can be estimated using available trios similarly as we
have estimated in Publication II.
We applied Haplous to ﬁnd SHs from three Finnish lymphoma families. Lymphoma is especially
well suited for haplotype analysis as some familial predisposition has been conﬁrmed in Hodgkin
lymphoma [139]. We identiﬁed SHs using a 100 SNP long window and assumed that the mutated SH
is shared at least by ﬁve individuals. This number requires the haplotype to be at least in two smaller
families or in one big family. To exclude IBS haplotypes, we excluded those SHs that were in three
control samples. This resulted in 1,288 chromosomal regions having SHs that were larger than 30
SNPs, which included 273 protein coding genes. We estimated that this region is signiﬁcantly shared
between individuals. We also used a text mining tool [119] to ﬁnd genes associated with lymphoma
terms. This resulted in seven genes. As molecular background of lymphoma is still largely unknown,
the risk variant may lay in other, yet unidentiﬁed, genes. However, we discovered that one of the
families does not extensively share haplotypes with two other families, thus, the members of this
family may carry a variant from diﬀerent origins.
We also compared the length of SHs from lymphoma families to the length of SHs shared by
multiple controls, and found that the longest SHs were found in cases. Based on an analytical
estimation, we also estimated that the interesting SHs that are shared by ﬁve or more family members
are signiﬁcant.
To compare Haplous with an existing method, Beagle [85], we simulated a chromosome for 100
families that are similar to our lymphoma analysis. Using this data, Haplous performed better in
terms of locating the mutated region. However, we recognize that Beagle is targeted to a very diﬀerent
purpose than Haplous, as it identiﬁes pairs of individuals and their IBD regions. This comparison
shows that an approach implemented in Haplous is needed in the ﬁeld of IBD analysis approaches.
The simulated data were also used to assess the performance of Haplous when the assumptions
in the study are wrong. We used three diﬀerent wrong assumptions: 1) Parameter values are too
stringent or too loose; 2) the number of controls is too low; and 3) some of the cases are in fact
unrelated controls. The stringent parameter values resulted in an increased number of FN with
increased speciﬁcity, which means that Haplous returned less results, but the mutation was discovered
more frequently and the location was more accurate. When the number of controls was reduced,
Haplous identiﬁed the mutation robustly, but the chromosomal location of the mutation was mapped
less precisely. In the worst cases, where cases and controls were mixed, Haplous did not return
anything, but when the assumptions nearly corresponded the data, the performance of Haplous
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increased rapidly to normal level.
When using Haplous, the parameter value selection can be done iteratively ﬁrst assuming the
most stringent conditions and then relaxing these criteria in next iterations. This way the ﬁrst results
ﬁnish very fast and they show the most striking features in haplotype sharing. The latter iterations
can be used to expand the information of haplotype sharing into regions that are less conﬁdently
IBD. Our results show that when the assumptions are far from reality, as might be the case in the
most stringent iteration, Haplous returns an empty result set instead of false positives. These results
increase the conﬁdence on our suggestion for iterative approach.
Currently, Haplous is applied to new research questions that are very diﬀerent than those presented
in the original publication. We have analyzed a large cohort of unrelated, or very distantly related,
people. We have also applied this approach to compare SHs between families by ﬁrst compiling a
pseudo-haplotype for each of the families. These recent applications show that Haplous is very ﬂexible
and can be applied to various research questions. Also, the current implementation of Haplous has a
new feature to ﬁlter SHs regardless to their homozygosity or heterozygosity.
5.3 Pooling gene expression datasets reveals novel markers for cell types
To get robust results for diﬀerential expression, a large enough number of samples is needed [140].
This number increases with the biological variability of the phenotypes, and with the amount of
gene expression change that has an impact on the phenotype [140]. Some recent studies are limited
only to a small number of samples, which was seen in our data pool, as one source study had only
two replicates for each treatment [141]. In Publication III we pooled gene expression microarray
measurements from multiple studies from a public database [34] to investigate the gene expression
diﬀerences between BECs and LECs, and to ﬁnd robust biomarkers to separate these cell types.
Although, BECs and LECs are separate, diﬀerentiated cell types, they originate from the same tissue
structure of endothelial cells [142]. During development, LECs separate from early vascular structures
and commit to their distinct gene expression proﬁles that create a LEC speciﬁc phenotype [142].
The work that enabled using the pooled set of gene expression samples required implementation of
a complete pipeline that produces information of the candidate BEC and LEC samples automatically
and allows monitoring the quality of data and interfering with the analysis. The integration of
several gene expression measurement platforms had obvious challenges to map genes with each other
and to acquire comparable expression values. Additional problems were caused by non-commercial
measurement platforms, unknown processing of the data, and meta data that is either missing or
very diﬃcult to access systematically. These challenges emphasize that integrating gene expression
measurement from several sources requires careful consideration and technical implementation that
enables managing gene expression data.
In the analysis of the pooled expression data, we identiﬁed 28 diﬀerentially expressed genes
(fold change ≥ 2 and multiple hypothesis corrected p-value ≤ 0.05), from which we validated two
genes (MCAM and COLEC12 ) using immunoﬂuorescence staining. Melanoma cell adhesion molecule
(MCAM ) was selectively expressed in BECs and not in LECs, and Collectin placenta 12 (COLEC12 )
was expressed in LECs and not in BECs. Although pooling the samples required many processing
steps, this validation shows that the gene expression analysis was able to identify two novel markers
for the cell types.
We compared the diﬀerentially expressed genes with genes found by three other analysis: two
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previously published studies [143, 144] and an analysis of only one gene expression microarray platform
from our dataset. Only few diﬀerentially expressed genes were found by our analysis and the previous
two studies. This shows that many assumptions used in sample processing, measurements and analysis
steps bring diﬀerent bias to the results as expected according to a previous study [140]. Furthermore,
diﬀerential expression is not a dichotomous state, but rather a continuous phenomenon, and gene
expression studies deﬁne the threshold that states where a gene becomes diﬀerentially regulated. The
diﬀerentially expressed genes from the analysis of our dataset as compared to only one gene expression
microarray platform also showed partial overlap.
Our analysis shows that pooling samples from multiple gene expression platforms can produce
reproducible gene expression biomarkers for a phenotype. This is especially useful since it allows
using published data sets, which can lead to increased sample sizes. This may also give a hint
of biological variability in the cell types as diﬀerent conditions produce somewhat alternated sets of
diﬀerentially expressed genes. Thus, these analyses are essential to discover the full molecular portrait
behind the phenotypes.
5.4 Artiﬁcial neural network classiﬁcation predicts phenotypes
In Publication IV we show how supervised machine learning can be used both to discover biomark-
ers and to understand complex relationships of molecular actors behind the phenotype. Methods from
other publications of this thesis produce lists of candidate markers that alone are not necessarily causal
or useful in practice [48]. Thus, biomarker discovery is an important step when identifying the molec-
ular background of a phenotype. This step produces very focused information of the biology and may
result relevant tools that can be brought to use in labs and clinics.
From the 4,095 marker combinations that were used for classiﬁcation, gene expression signature
of FoxP3, Nfat-C2, IL-16, and GATA-3 produced the best predictive classiﬁer for cow's milk allergy
(CMA) persistency. However, in our study, selecting the optimal classiﬁer was challenging, since we
classiﬁed three diﬀerent outcomes (non-atopic, tolerant CMA and persistent CMA). The classiﬁcation
result was a trade-oﬀ between the classes. When one class is predicted with high accuracy, two other
classes may produce very poor classiﬁcation. In our study misclassiﬁcation between non-atopic and
persistent CMA was considered a more serious error than mixing tolerant CMA with other groups.
Here, we chose to favor the correct prediction of persistent CMA patients and minimize false positive
prediction of CMA persistency outcome. In practice, we chose the best classiﬁcation outcome using
κ−value that favors overall correct separation of classes. The quality of classiﬁcation was inspected
from a confusion matrix, which resulted 12 persistent CMA patients classiﬁed correctly and one
patient predicted to a healthy and one to tolerant group. Also, one tolerant and one non-atopic
patient were falsely predicted to belong to persistent CMA group. Second best classiﬁcation had
already three non-atopic patients classiﬁed to persistent CMA group (ﬁve FP in total) although 14
persistent CMA patients were correctly classiﬁed. We concluded that this classiﬁer identiﬁes processes
related to persistent CMA poorly. This data was suitable for supervised learning approach, since the
phenotype, i.e. disease outcome, of the patients was known. Therefore we were able to use this
information to identify complex biomarker combinations that best predict this phenotype.
Here, we were able to enumerate all possible gene combinations to ﬁnd the optimal predictive
gene expression signature. In a concurrent study [145], we created a classiﬁer to predict the CMA
recovery based on antibody binding on protein epitopes . This study had measurements from 289
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epitopes, thus enumerating all epitope combinations was not possible. This required the use of a
feature selection algorithm to select the most relevant epitopes for classiﬁcation [145]. The feature
selection is a typical step when using supervised machine learning.
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The focus of this thesis is phenotype. Although the molecular mechanisms in cells can be studied
from purely intellectual aspects, usually the interest rises from very practical questions regarding the
phenotype. Diseases are in particular focus, since targeted treatments would increase the life span
or life quality of many people. In these cases, the molecular mechanisms aﬀecting the phenotype
are sought because repairing the disease causing molecules would be the needed treatment. Some
encouraging examples for targeted treatments exist already in cancers such as melanoma [137] or
breast cancer [146], where the speciﬁc molecular signature leads to treatment with a speciﬁc drug.
Also, the diagnostic markers can improve the life quality when a treatment can be targeted to those
that beneﬁt from it and others will be spared from unnecessary side eﬀects [49].
This thesis presents a panel of computational methods to discover the molecular background
of phenotypes. These methods generate candidate genes based on information from genetics, gene
expression and systems biology. These candidate genes can then be subjected to more detailed
analyses in order to discover clinically relevant tools. Hence, this work provides new access to existing
knowledge that will integrate systems biology into data analysis and interpretation of the results. This
has been considered as a beneﬁcial approach [77, 76], and its importance will increase as the quality
and coverage of biological knowledge bases increases at the same time as studies will scale up and
include increasingly heterogeneous measurements.
This work complements current methods to map inherited genetic variants to phenotypes in a
research setting where traditional statistical methods can not be applied. These statistical methods
have been very successful when studying high-penetrance Mendelian diseases or common variants in
large populations, however, striking Mendelian disorders are mainly exhausted as a research material
and common variants explain only a small fraction of inheritance [82]. These realizations accompanied
by sequencing technologies have pushed the research towards ﬁnding rare variants in small families
or studying isolated somatic events. The work in this thesis provides a method for the ﬁrst types
of studies, where IBD is used as a way to identify the inherited causal variation. Haplous can be
applied to sequencing data, especially because it accepts multiallelic variants and its memory and
time demand increases only linearly with the number of markers. This ability to accept multiallelic
markers has already been exploited in an unpublished study of comparing pseudo-haplotypes between
families.
The identiﬁcation of inherited causal variants is hardly enough for understanding the phenotype,
thus, cell type speciﬁc information of gene functions is needed. This was demonstrated in a recent
study, where the same mutation in melanoma or colorectal cancer requires diﬀerent treatments because
of tissue speciﬁc gene activation [136]. The work in this thesis also presents a gene expression analysis
of cell types by pooling multiple datasets from previously published studies. This approach utilizes
scattered published gene expression studies that individually may have quite a small number of
samples. When these are pooled together, the result may capture more of the biological variation
and bring more power to statistical tests.
Finally, while understanding the biological background in phenotypes is in itself interesting, an-
other important goal in biomedical research is to ﬁnd biomarkers. In this step, a vast number of
candidate molecules is turned into practical information with for example machine learning. In some
cases this will also give new insights on the molecular mechanisms.
The essential characteristics of science is reproducibility and accumulation of knowledge that
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create a cycle where hypotheses are tested and revised in the light of new information. Publication
III is an example of such a case, revising the current paradigms, as we could show that the widely
used practice to study immortalized cell lines may lead into false results.
Computational methods should support this iterative process. All the methods in this thesis are
implemented on the Anduril workﬂow engine [105], which enables the application of these methods
eﬀortlessly on constantly evolving datasets. An example of re-execution was given in this thesis when
the list of focal genes for Publication I was recreated using the most recent information. Here we
can see that incomplete understanding of the molecular pathways has been complemented with new
information, but still much remains to be discovered. All of the methods are freely available, and
they can be integrated to other analyses pipelines in Anduril.
Eﬀorts are currently focused on analyzing individuals with clearly genetically determined diseases
to shed light on the molecular background of these diseases, but also they are expected to bring
a novel treatment for aﬀected people [58, 82, 147]. This has also pushed medicine to ﬁnd person-
alized treatments [147, 148, 149], which can be extended to provide personalized genetics also to
healthy people [150]. In addition, personalized genetics can be accompanied with gene expression
measurements, which are essential especially in cancer genetics [148]. The terabyte-level of data pro-
duced by these measurement technologies have increased the importance of computational methods
in understanding the molecular functions and isolating the driving molecules or clinically relevant
biomarkers. The importance of using existing biological knowledge to pinpoint candidates from such
analyses has been recognized to be a key component in ongoing biomedical projects [147, 149]. A
diagnosis pipeline intended for clinical use has already integrated existing biological knowledge with
a complete whole-genome sequence analysis [149]. In the near future, heterogeneous measurements,
such as protein binding, protein expression or spatiotemporal information from biological processes,
can be integrated with genome information and gene expression datasets. Extracting knowledge from
these data will require extensive models that take into consideration the dynamic nature of biology.
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